Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?

OBJECTIVE: Osteoarthritis (OA) is heterogeneous disease, for which drug development has proven to be challenging, both facilitated and hampered by changing guidelines. This is evident by the current lack of approved treatments, which improve joint function and delay joint failure. There is a need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Karsdal, M.A., Tambiah, J., Hochberg, M.C., Ladel, C., Bay-Jensen, A.C., Arendt-Nielsen, L., Mobasheri, A., Kraus, V.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
ORIGINAL PAPER
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718257/
https://www.ncbi.nlm.nih.gov/pubmed/36474940
http://dx.doi.org/10.1016/j.ocarto.2022.100262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718257/
https://www.ncbi.nlm.nih.gov/pubmed/36474940
http://dx.doi.org/10.1016/j.ocarto.2022.100262

Ejemplares similares